- Home
- SQNS vs KPTI Comparison
SQNS vs KPTI Comparison
Compare SQNS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- KPTI
- Stock Information
- Founded
- SQNS 2003
- KPTI 2008
- Country
- SQNS France
- KPTI United States
- Employees
- SQNS N/A
- KPTI N/A
- Industry
- SQNS Semiconductors
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- SQNS Technology
- KPTI Health Care
- Exchange
- SQNS Nasdaq
- KPTI Nasdaq
- Market Cap
- SQNS 147.0M
- KPTI 44.5M
- IPO Year
- SQNS 2011
- KPTI 2013
- Fundamental
- Price
- SQNS $9.45
- KPTI $6.16
- Analyst Decision
- SQNS Buy
- KPTI Buy
- Analyst Count
- SQNS 1
- KPTI 6
- Target Price
- SQNS $3.50
- KPTI $39.80
- AVG Volume (30 Days)
- SQNS 4.2M
- KPTI 102.1K
- Earning Date
- SQNS 11-04-2025
- KPTI 11-04-2025
- Dividend Yield
- SQNS N/A
- KPTI N/A
- EPS Growth
- SQNS N/A
- KPTI N/A
- EPS
- SQNS 1.85
- KPTI N/A
- Revenue
- SQNS $37,325,000.00
- KPTI $137,269,000.00
- Revenue This Year
- SQNS N/A
- KPTI $3.67
- Revenue Next Year
- SQNS $89.05
- KPTI $9.40
- P/E Ratio
- SQNS $0.52
- KPTI N/A
- Revenue Growth
- SQNS 32.07
- KPTI N/A
- 52 Week Low
- SQNS $0.73
- KPTI $3.51
- 52 Week High
- SQNS $5.83
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- SQNS 95.28
- KPTI 50.82
- Support Level
- SQNS $0.93
- KPTI $6.15
- Resistance Level
- SQNS $0.89
- KPTI $6.85
- Average True Range (ATR)
- SQNS 0.10
- KPTI 0.51
- MACD
- SQNS 0.59
- KPTI -0.15
- Stochastic Oscillator
- SQNS 97.05
- KPTI 19.49
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.